{"filing":{"accession_number":"0001648257-26-000064","cik":"0001648257","ticker":"HMDCF","company_name":"HUTCHMED (China) Ltd","form":"6-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"hcm-20260929x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1648257/000164825726000064/hcm-20260929x6k.htm"},"events":[{"id":35560,"run_id":32758,"accession_number":"0001648257-26-000064","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces AstraZeneca's submission of a US NDA for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) for MET-driven EGFR-mutated lung cancer, supported by positive Phase III SAFFRON trial results showing statistically significant improvements in progression-free and overall survival. This is a material regulatory milestone and product development event for HUTCHMED's co-developed therapeutic, but does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It represents a significant operational/strategic advancement in the clinical development and regulatory pathway for a key pipeline asset.","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-09-29","form":"6-K","submitted_at":null,"items":[{"id":39649,"accession_number":"0001648257-26-000064","item_number":"EX-99.1","item_title":"hcm-ex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces AstraZeneca's submission of a US NDA for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) for MET-driven EGFR-mutated lung cancer, supported by positive Phase III SAFFRON trial results showing statistically significant improvements in progression-free and overall survival. This is a material regulatory milestone and product development event for HUTCHMED's co-developed therapeutic, but does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It represents a significant operational/strategic advancement in the clinical development and regulatory pathway for a key pipeline asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-29T10:08:12.526043+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39649,"accession_number":"0001648257-26-000064","item_number":"EX-99.1","item_title":"hcm-ex99d1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces AstraZeneca's submission of a US NDA for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) for MET-driven EGFR-mutated lung cancer, supported by positive Phase III SAFFRON trial results showing statistically significant improvements in progression-free and overall survival. This is a material regulatory milestone and product development event for HUTCHMED's co-developed therapeutic, but does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or financial obligation). It represents a significant operational/strategic advancement in the clinical development and regulatory pathway for a key pipeline asset.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-29T10:08:12.526043+00:00","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-09-29"}]}